Severity
Low
FDA Drug recall · Reported November 3, 2021
Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid.
Ultra Seal Corporation recalled ZEE+ painaid ESF Extra-Strength Formula (Acetaminophen 250 mg, Aspirin 250 mg (NSAID), Ca… - a low-severity action.
ZEE+ painaid ESF Extra-Strength Formula (Acetaminophen 250 mg, Aspirin 250 mg (NSAID), Ca… was recalled by Ultra Seal Corporation in November 3, 2021. Reason: Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic…. Check the official notice for the remedy. Verify recall #D-0072-2022 with the FDA Drug before acting.
The recall
Ultra Seal Corporation issued this low-severity FDA Drug recall-Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic….
Sourced from official FDA Drug enforcement records. Verify recall #D-0072-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0072-2022) was formally reported on November 3, 2021, with the manufacturer initiating the action on October 13, 2021. It is classified under Low severity (Class III), with a current status of Terminated. Ultra Seal Corporation is listed as the recalling firm, operating out of New Paltz, NY. Federal records list the affected scope as 1,968,150 tablets.
The documented reason for this recall is: Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid. Distribution data in the federal record shows the product reached: Nationwide in the USA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
1,968,150 tablets
Related Recalls
6
5 from same agency
ZEE+ painaid ESF Extra-Strength Formula (Acetaminophen 250 mg, Aspirin 250 mg (NSAID), Caffeine 65 mg) tablets, 2 Tablets per/package, Packaged in a) 50-count packages/carton, b) 125-count packages/carton, PA-ESF 1414Z, Dist. by: Zee Medical Distributors, LLC Mason, OH 45040 (Shipping Label)
Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0072-2022 |
| Date reported | November 3, 2021 |
| Date initiated | October 13, 2021 |
| Recalling firm | Ultra Seal Corporation |
| Firm location | New Paltz, NY |
| Affected scope | 1,968,150 tablets |
| Distribution | Nationwide in the USA. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 3, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.